JP2018183178A5 - - Google Patents

Download PDF

Info

Publication number
JP2018183178A5
JP2018183178A5 JP2018144099A JP2018144099A JP2018183178A5 JP 2018183178 A5 JP2018183178 A5 JP 2018183178A5 JP 2018144099 A JP2018144099 A JP 2018144099A JP 2018144099 A JP2018144099 A JP 2018144099A JP 2018183178 A5 JP2018183178 A5 JP 2018183178A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
hydrate
acceptable salt
antisense oligomer
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018144099A
Other languages
English (en)
Japanese (ja)
Other versions
JP6977998B2 (ja
JP2018183178A (ja
Filing date
Publication date
Priority claimed from JP2017539975A external-priority patent/JP6384845B2/ja
Application filed filed Critical
Publication of JP2018183178A publication Critical patent/JP2018183178A/ja
Publication of JP2018183178A5 publication Critical patent/JP2018183178A5/ja
Priority to JP2021179353A priority Critical patent/JP2022033738A/ja
Application granted granted Critical
Publication of JP6977998B2 publication Critical patent/JP6977998B2/ja
Priority to JP2023218764A priority patent/JP2024038104A/ja
Priority to JP2025197087A priority patent/JP2026032058A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018144099A 2015-09-15 2018-07-31 アンチセンス核酸 Active JP6977998B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021179353A JP2022033738A (ja) 2015-09-15 2021-11-02 アンチセンス核酸
JP2023218764A JP2024038104A (ja) 2015-09-15 2023-12-26 アンチセンス核酸
JP2025197087A JP2026032058A (ja) 2015-09-15 2025-11-18 アンチセンス核酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015182145 2015-09-15
JP2015182145 2015-09-15
JP2017539975A JP6384845B2 (ja) 2015-09-15 2016-09-15 アンチセンス核酸

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017539975A Division JP6384845B2 (ja) 2015-09-15 2016-09-15 アンチセンス核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021179353A Division JP2022033738A (ja) 2015-09-15 2021-11-02 アンチセンス核酸

Publications (3)

Publication Number Publication Date
JP2018183178A JP2018183178A (ja) 2018-11-22
JP2018183178A5 true JP2018183178A5 (https=) 2019-10-31
JP6977998B2 JP6977998B2 (ja) 2021-12-08

Family

ID=58289325

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539975A Active JP6384845B2 (ja) 2015-09-15 2016-09-15 アンチセンス核酸
JP2018144099A Active JP6977998B2 (ja) 2015-09-15 2018-07-31 アンチセンス核酸
JP2021179353A Withdrawn JP2022033738A (ja) 2015-09-15 2021-11-02 アンチセンス核酸
JP2023218764A Pending JP2024038104A (ja) 2015-09-15 2023-12-26 アンチセンス核酸
JP2025197087A Pending JP2026032058A (ja) 2015-09-15 2025-11-18 アンチセンス核酸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017539975A Active JP6384845B2 (ja) 2015-09-15 2016-09-15 アンチセンス核酸

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021179353A Withdrawn JP2022033738A (ja) 2015-09-15 2021-11-02 アンチセンス核酸
JP2023218764A Pending JP2024038104A (ja) 2015-09-15 2023-12-26 アンチセンス核酸
JP2025197087A Pending JP2026032058A (ja) 2015-09-15 2025-11-18 アンチセンス核酸

Country Status (29)

Country Link
US (4) US10144931B2 (https=)
EP (2) EP3778895A1 (https=)
JP (5) JP6384845B2 (https=)
KR (3) KR20220053048A (https=)
CN (3) CN108026531B (https=)
AU (1) AU2016324800B2 (https=)
CA (1) CA2996280C (https=)
CO (1) CO2018002557A2 (https=)
CY (1) CY1123119T1 (https=)
DK (1) DK3351633T3 (https=)
ES (1) ES2808049T3 (https=)
HR (1) HRP20201125T1 (https=)
HU (1) HUE050061T2 (https=)
IL (1) IL258065B (https=)
LT (1) LT3351633T (https=)
MX (1) MX391304B (https=)
MY (1) MY185390A (https=)
PH (1) PH12018500568B1 (https=)
PL (1) PL3351633T3 (https=)
PT (1) PT3351633T (https=)
RS (1) RS60493B1 (https=)
RU (1) RU2724554C2 (https=)
SG (1) SG11201802138TA (https=)
SI (1) SI3351633T1 (https=)
SM (1) SMT202000379T1 (https=)
TW (1) TWI725990B (https=)
UA (1) UA123359C2 (https=)
WO (1) WO2017047707A1 (https=)
ZA (1) ZA201801682B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3351633T1 (sl) * 2015-09-15 2020-09-30 Nippon Shinyaku Co., Ltd. Protismiselna nukleinska kislina
JP7511326B2 (ja) 2015-10-09 2024-07-05 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物およびその方法
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
GB201821269D0 (en) * 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
US12497615B2 (en) 2019-04-25 2025-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
JP7842395B2 (ja) * 2019-12-19 2026-04-08 日本新薬株式会社 エクソンスキッピングを可能にするアンチセンス核酸
US20230140736A1 (en) * 2020-02-28 2023-05-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
MX2023012559A (es) 2021-04-30 2023-12-15 Sarepta Therapeutics Inc Métodos de tratamiento para la distrofia muscular.
WO2022270585A1 (ja) * 2021-06-23 2022-12-29 日本新薬株式会社 アンチセンスオリゴマーの組み合わせ
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3244382A1 (en) 2021-12-27 2025-02-26 Nippon Shinyaku Co., Ltd. PROCESS FOR THE PRODUCTION OF OLIGONUCLEIC ACID COMPOUNDS
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
JP2025509438A (ja) 2022-03-17 2025-04-11 サレプタ セラピューティクス, インコーポレイテッド ホスホロジアミデートモルホリノオリゴマーコンジュゲート
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567664A (en) 1948-04-22 1951-09-11 Willis G Ewell Chicken culling device
JP3398378B2 (ja) 1989-12-20 2003-04-21 アンチビラルス・インコーポレイテツド リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体,デバイス及び医薬組成物
JP2000325085A (ja) * 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
JP4777777B2 (ja) 2002-11-25 2011-09-21 雅文 松尾 mRNA前駆体のスプライシングを修飾するENA核酸医薬
CA2524255C (en) * 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
EP1811024A1 (en) 2004-10-05 2007-07-25 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and medicinal composition
WO2006129594A1 (ja) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. 核酸含有複合体製剤の製造方法
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
US8466255B2 (en) 2007-02-05 2013-06-18 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2008317566B2 (en) * 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN112574988A (zh) 2008-10-24 2021-03-30 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
JP5786109B2 (ja) 2008-10-27 2015-09-30 プロセンサ テクノロジーズ ベー.フェー. Duchenne型筋ジストロフィーmRNA前駆体のエクソン45の効率的なスキッピングのための方法及び手段
CA2759899A1 (en) * 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
ITTO20090487A1 (it) * 2009-06-26 2010-12-27 Univ Ferrara Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd)
US20120270930A1 (en) * 2009-10-29 2012-10-25 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods and compositions for dysferlin exon-skipping
LT2499249T (lt) 2009-11-12 2018-12-27 The University Of Western Australia Priešprasmės molekulės ir patologijų gydymo būdai
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP2672977A1 (en) * 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
CN117721110A (zh) * 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP2870246B1 (en) 2012-07-03 2019-09-11 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
CA2906812A1 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
SMT201900169T1 (it) 2014-03-12 2019-05-10 Nippon Shinyaku Co Ltd Acido nucleico antisenso
JP2015182145A (ja) 2014-03-20 2015-10-22 キヤノン株式会社 ロボットシステムの制御方法、およびロボットシステム
RU2695430C2 (ru) 2014-06-17 2019-07-23 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
SI3351633T1 (sl) * 2015-09-15 2020-09-30 Nippon Shinyaku Co., Ltd. Protismiselna nukleinska kislina

Similar Documents

Publication Publication Date Title
JP2018183178A5 (https=)
HRP20160336T1 (hr) Protusmjerna nukleinska kiselina
RU2018113276A (ru) Антисмысловая нуклеиновая кислота
RU2017101172A (ru) Антисмысловые нуклеиновые кислоты
JP2020022483A5 (https=)
JP2016502858A5 (https=)
RU2014130600A (ru) Антисмысловые нуклеиновые кислоты
JP2020072724A5 (https=)
JP2015514418A5 (https=)
RU2019130513A (ru) Антисмысловые нуклеиновые кислоты
JPWO2022270585A5 (https=)
JP2017525705A5 (https=)
JP2016517279A5 (https=)
JPWO2022099159A5 (https=)
JP2018528781A5 (https=)
JP2016533761A5 (https=)
JP2013510561A5 (https=)
JP2019534009A5 (https=)
JP2018520685A5 (https=)
JP2018529732A5 (https=)
JP2012508560A5 (https=)
JP2011529703A (ja) アンチセンスオリゴヌクレオチドによるToll様受容体8発現の調節
JP2013535212A5 (https=)
JP2012506703A5 (https=)
IL316808A (en) Modified double-stranded RNA materials and their uses